Antimicrobial activity of N-phthaloylamino acid hydroxamates

Acta Pharmaceutica

Volumn 55, Issue 4, 2005, Pages 387-399

  Matijević Sosa, Julija ^a   Cvetnić, Zdenka ^a  

^a UNIVERSITY OF ZAGREB   (Croatia)

Author keywords

Antibacterial activity; Hydroxamic acid; Lipophilicity; Phthalimide

Indexed keywords

AMINO ACID DERIVATIVE; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; BACTERIAL ENZYME; BACTERIAL RNA; HYDROXAMIC ACID DERIVATIVE; N PHTHALOYL BETA ALANINE HYDROXAMIC ACID; N PHTHALOYL DEXTRO PHENYLGLYCINE HYDROXAMIC ACID; N PHTHALOYLGLYCINE HYDROXAMIC ACID; PHTHALIMIDE; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ANTIFUNGAL ACTIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG SCREENING; DRUG SENSITIVITY; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; GROWTH INHIBITION; IN VITRO STUDY; LIPOPHILICITY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; YEAST; YERSINIA ENTEROCOLITICA;

EID: 29244451071     PISSN: 13300075     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. O. L. Hoffmann and A. E. Smith, A new group of plant growth regulators, Science 109 (1949) 588.
2. H. Koch, Phytopharmakologische Untersuchung von Thalidomid, seinen Metaboliten and einigen strukturverwandten Verbindungen, Sci. Pharm. 39 (1971) 209-247.
3. Lj. Butula, N. Kujundzic, M. Malnar and I. Vukusid, Mitodepressive effect of some N-substi-tuted phthalimides on Lepidium sativum L., Pharmazie 30 (1975) 753.
4. T. Midtvet, The effect of thalidomide on the growth curve of a riboflavine-dependent microbe, Acta Pathol. Microbiol. Scand. 58 (1963) 355-362.
5. P. Kant and R. K. Saksena, Synthesis and antimicrobial activity of some new 2-phenyl-3-p-(2′-methyl-3′-aryl-4′-oxo-thiazolin-2′- yl) phenyl-quinazolin-4-ones and 2-phenyl-3-p-(1′-aryl-3-phthalimido- 4′-methylazetidin-2′-one-2′-yl) phenyl-quinazolin-4-ones, Indian J. Het. Chem. 12 (2003) 315-318.
6. G. L. Kennedy, J. R. D. W. Arnold and M. L. Keplinger, Mutagenicity studies with captan, captofol, folpet and thalidomide, Food Cosmet. Toxicol. 13 (1975) 55-61.
7. E. Fernandez-Martinez, M. S. Morales-Rios, V. Perez-Alvarez and P. Muriel, Effects of thalidomide and 3-phthalimido-3-(3,4-dimethoxyphenyl)- propanamide on bile duct obstruction-induced cirrhosis in the rat, Drug Dev. Res. 54 (2001) 209-218.
8. E. R. Lepper, S. S. W. Ng, M. Gutschow, M. Weiss, S. Hauschildt, T. K. Hecker, F. A. Luzzio, K. Eger and W. D. Figg, Comparative molecular field analysis and comparative molecular similarity indices analysis of thalidomide analogues as angiogenesis inhibitors, J. Med. Chem. 47 (2004) 2219-2227.
9. X. X. Zhu, T. Giordano, Q. S. Yu, H. W. Holloway, T. A. Perry, D. K. Lahiri, A. Brossi and N. H. Greig, Thiothalidomides: Novel isosteric analogues of thalidomide with enhanced TNF-alpha inhibitory activity, J. Med. Chem. 46 (2003) 5222-5229.
10. M. E. Franks, G. R. Macpherson and W. D. Figg, Thalidomide, Lancet 363 (2004) 1802-1811.
11. M. Sayarlioglu, M. C. Kotan, N. Totcu, H. Arslanturk and A. Gul, Treatment of recurrent perforat-ing intestinal ulcers with thalidomide in Behcet's disease, Ann. Pharmacother. 38 (2004) 808-811.
12. R. Srinivasan and G. R. Lichtenstein, Recent developments in the pharmacological treatment of Crohn's disease, Expert Opin. Investig. Drugs 13 (2004) 373-391.
13. K. Q. Lu, S. Brennenman, R. Burns, A. Vink, E. Gaines, A. Haake and A. Gaspari, Thalidomide inhibits UVB-induced mouse keratinocyte apoptosis by both TNF-alpha-dependent and TNF-alpha-independent pathways, Photoderm. Photoimm. Photomed. 19 (2003) 272-280.
14. H. R. Gockel, A. Lugering, J. Heidemann, M. Schmidt, W. Domschke, T. Kucharzil and N. Lugering, Thalidomide induced apoptosis in human monocytes by using a cytochrome c-dependent patway, J. Immunol. 172 (2004) 5103-5109.
15. A. R. Kerr and J. A. Ship, Management strategies for HIV-associated aphthous stomatitis, Am. J. Clin. Dermat. 4 (2003) 669-680.
16. L. Tsenova, A. Bergtold, V. H. Freedman, R. A. Young and G. Kaplan, Tumor necrosis factor alpha is a determinant of pathogenesis and disease progression in mycobacterial infection in the central nervous system, Proc. Natl. Acad. Sci. USA 96 (1999) 5657-5662.
17. Y. S. Kim, J. S. Kim, H. C. Jung and I. S. Song, The effects of thalidomide on the stimulation of NF-kappa B activity and TNF-alpha production by lipopolysaccharide in the human colonic epithelial cell line, Mol. Cells 17 (2004) 210-216.
18. A. Orzeszko, J. Vilpo, L. Vilpo and B. Kaminska, Synthesis and anticancer activity of 5′-phthaloyl-nucleosides, Pharmazie 58 (2003) 169-172.
19. P. Yogeeswari, D. Sriram, V. Saraswat, J. V. Ragavendran, M. M. Kumar, S. Murugesan, R. Thirumurugan and J. P. Stables, Synthesis and anticonvulsant and neurotoxicity evaluation of N-4-phthalimido phenyl (thio) semicarbazides, Eur. J. Pharm. Sci. 20 (2003) 341-346.
20. S. Lentzsch, M. S. Rogers, R. LeBlanc, A. E. Birsner, J. H. Shah, A. M. Treston, K. C. Anderson and R. J. D'Amato, S-3-amino-phthalimido-glutarimide inhibits angiogenesis and growth of B-cell neoplasias in mice, Cancer Res. 62 (2002) 2300-2305.
21. J. N. Neilands, Hydroxamic acids in nature, Science 156 (1967) 1443-1447.
22. Z. Eckstein and T. Urbanski, The biological active naturally occurring and synthetic hydroxamic acid derivatives, Wiad. Chem. 37 (1983) 348-388.
23. E. M. F. Muri, M. J. Nieto, R. D. Sindelar and J. S. Williamson, Hydroxamic acids as pharmacological agents, Curr. Med. Chem. 9 (2002) 1631-1653.
24. I. A. Butovich and C. C. Reddy, Inhibition of potato lipoxygenase by linoleyl hydroxamic acid kinetic and EPR spectral evidence for a two-sted reaction, Biochem. J. 365 (2002) 865-871.
25. M. Dimartino, C. Wolff, W. High, G. Stroup, S. Hoffman, J. Laydon, J. C. Lee, D. Bertolini, W. A. Galloway, M. J. Crimmin, M. Davis and S. Davis, Anti-arthritic activity of hydroxamic acid-based pseudopeptide inhibitors of matrix metalloproteinases and TNF-α processing, Inflamm. Res. 46 (1997) 211-215.
26. S. Odake, T. Morikawa, M. Tsuchiya, I. Imamura and K. Kobashi, Inhibition of Helicobacter pylori urease by hydroxamic acid derivatives, Biol. Pharm. Bull. 17 (1994) 1329-1332.
27. M. Arnold, D. A. Brown, O. Deeg, W. Errington, W. Haase, K. Herlihy, T. J. Kemp, H. Nimir and R. Werner, Hydroxamate-bridged dinuclear nickel complexes as models for urease inhibition, Inorg. Chem. 37 (1998) 2920-2925.
28. E. M. F. Muri, H. Mishra, S. M. Stein and J. S. Williamson, Molecular modeling, synthesis and biological evaluation of heterocyclic hydroxamic acids designed as Helicobacter pylori urease inhibitors, Lett. Drug Des. Disc. 1 (2004) 30-34.
29. E. Jabri, M. B. Carr, R. P. Hausinger and R. A. Karplus, The crystal structure of urease from Klebsiella aerogenes, Science 268 (1995) 998-1004.
30. M. C. Pirrung, L. N. Turney, A. L. McClerren and C. R. H. Raetz, High-throughput catch and release synthesis of oxazoline hydroxamates. Structure-activity relationships in novel inhibitors of Escherichia coli LpxC: In vitro enzyme inhibition and antibacterial properties, J. Am. Chem. Soc. 125 (2003) 1575-1586.
31. J. E. Jackman, C. R. H. Raetz and C. A. Fierke, Site-directed mutagenesis of the bacterial metalloamidase UDP-(3-O-acyl)-N-acetylglucosamine deacetylase (LpxC). Identification of the zinc binding site, Biochemistry 40 (2001) 514-523.
32. C. P. McClure, K. M. Rusche, K. Peariso, J. E. Jackman, C. A. Fierke and J. E. Penner-Hahn, EXAFS studies of the zinc sites of UDP-(3-O-acyl)-N- acetylglucosamine deacetylase (LpxC), J. Inorg. Biochem. 94 (2003) 78-85.
33. D. A. Whittington, K. M. Rusche, H. Shin, C. A. Fierke and D. W. Christianson, Crystal structure of LpxC, a zinc-dependent deacetylase essential for endoxin biosynthesis, Proc. Nat. Acad. Sci. 100 (2003) 8146-8150.
34. C. R. H. Raetz, Bacterial endotoxins: Extraordinary lipids that activate eucaryotic signal transduction, J. Bacteriology 175 (1993) 5745-5753.
35. F. Dardel, S. Ragusa, C. Lazennec, S. Blanquet and T. Meinnel, Solution structure of nickel-peptide deformylase, J. Mol. Biol. 280 (1998) 501-513.
36. A. Becker, I. Schlichting, W. Kabsch, D. Groche, S. Schultz and A. F. V. Wagner, Iron center, substrate recognition and mechanism of peptide deformylase, Nat. Struct. Biol. 5 (1998) 1053-1058.
37. M. K. Gupta, P. Mishra, P. Prathipati and A. K. Saxena, 2D-QSAR in hydroxamic acid derivatives as peptide deformylase inhibitors and antibacterial agents, Bioorg. Med. Chem. 10 (2002) 3713-3716.
38. J. Matijevic-Sosa and Lj. Butula, Synthesis and mitodepressive activity of some phthalimido-alkanehydroxamic acids, Acta Pharm. 43 (1993) 185-194.
39. th ed., Council of Europe, Strasbourg 2002, pp. 160-161.
40. L. M. Prescott, J. P. Harley and D. A. Klein, Microbiology, Wm. C. Brown Publishers, Dubuque 1993, pp. 328.
41. S. Nikolić, M. Medić-Šarić and J. Matijević-Sosa, QSPR and QSAR study of phthalimidohydroxamic acids, Acta Pharm. 45 (1995) 15-24.